A star drug in Mallinck­rodt’s $1.2B Su­cam­po buy­out flops in piv­otal tri­al

Some of the in­sid­ers at Mallinck­rodt $MNK may be won­der­ing to­day why they paid $1.2 bil­lion for Su­cam­po just 10 months ago. One of the two late-stage drugs they bagged in the deal has failed the reg­is­tra­tion study for of­ten fa­tal cas­es of Nie­mann-Pick type C.

Billed as a rel­a­tive­ly eco­nom­i­cal ap­proach to build­ing their late-stage pipeline, Mallinck­rodt — which was drummed out of PhRMA af­ter be­com­ing a punch­ing bag for crit­ics due to its pric­ing strat­e­gy — told in­vestors Tues­day that VTS-270 flopped in the reg­is­tra­tion study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER